Nuvectis Pharma (NVCT) Net Cash Flow (2021 - 2026)
Nuvectis Pharma (NVCT) posted Net Cash Flow of -$6.5 million for Q1 2026, down 70.8% sequentially from -$3.8 million in Q4 2025, and down 157.4% YoY from $11.3 million in Q1 2025.
Nuvectis Pharma (NVCT) Net Cash Flow (2021 - 2026) Analysis & Trends
Nuvectis Pharma has reported Net Cash Flow for 6 years, with the latest figure at -$6.5 million in Q1 2026.
- Quarterly Net Cash Flow fell 157.4% year-over-year to -$6.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$4.7 million (down 145.52% YoY) and the FY2025 annual result came in at $13.1 million, up 2309.27% from the prior year.
- Net Cash Flow retreated to -$6.5 million in Q1 2026 per NVCT's latest filing, from -$3.8 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $11.3 million in Q1 2025 and troughed at -$6.5 million in Q1 2026.
- A 5-year average of $1.1 million and a median of -$1.3 million in 2024 frame the typical range for Net Cash Flow.
- The widest YoY moves for Net Cash Flow: up 3252.37% in 2025, down 379.18% in 2025.
- Over 5 years, Net Cash Flow stood at -$3.6 million in 2022, then climbed by 19.58% to -$2.9 million in 2023, then soared by 146.51% to $1.4 million in 2024, then plunged by 379.18% to -$3.8 million in 2025, then tumbled by 70.8% to -$6.5 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$6.5 million, -$3.8 million, and $8.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Nuvectis Pharma | 506.13 Mn | 506.13 Mn | - | -2.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.97 Mn |
| Jun 30, 2026 | -2.97 Mn |
| Mar 31, 2026 | -6.50 Mn |
| Mar 31, 2026 | -6.50 Mn |
| Dec 31, 2025 | -3.81 Mn |
| Dec 31, 2025 | -3.81 Mn |
| Sep 30, 2025 | 8.65 Mn |
| Sep 30, 2025 | 8.65 Mn |
| Jun 30, 2025 | -3.07 Mn |
| Jun 30, 2025 | -3.07 Mn |
| Mar 31, 2025 | 11.33 Mn |
| Mar 31, 2025 | 11.33 Mn |
| Dec 31, 2024 | 1.36 Mn |
| Dec 31, 2024 | 1.36 Mn |
| Sep 30, 2024 | -947,000.00 |
| Sep 30, 2024 | -947,000.00 |
| Jun 30, 2024 | -1.35 Mn |
| Jun 30, 2024 | -1.35 Mn |
| Mar 31, 2024 | 338,000.00 |
| Mar 31, 2024 | 338,000.00 |